Synbio Tech Inc. (TPEX:1295)

Market Cap	2.36B -0.9%
Revenue (ttm)	1.04B +5.0%
Net Income	175.97M +3.4%
EPS	5.28 -2.2%
Shares Out	34.48M
PE Ratio	12.97
Forward PE	n/a
Dividend	3.50 (5.03%)
Ex-Dividend Date	Mar 27, 2026

Volume	65,242
Average Volume	82,152
Open	69.70
Previous Close	69.60
Day's Range	68.10 - 69.80
52-Week Range	58.50 - 157.50
Beta	1.13
RSI	30.80
Earnings Date	Mar 27, 2026

About Synbio Tech

Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional strain includes SynForU-MemoryUp, a solution for brain health; Lactobacillus plantarum TWK10 for exercise performance; ABKEFIR to improve digestive and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 92
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1295

Financial Performance

In 2025, Synbio Tech's revenue was 1.04 billion, an increase of 4.97% compared to the previous year's 989.48 million. Earnings were 175.97 million, an increase of 3.43%.